Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin.

about

Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin.

Item

http://www.wikidata.org/entity/Q51295262

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Open-label randomized non-infe ...... is uncontrolled on metformin.

@en

Open-label randomized non-infe ...... is uncontrolled on metformin.

@nl

type

Item

label

Open-label randomized non-infe ...... is uncontrolled on metformin.

@en

Open-label randomized non-infe ...... is uncontrolled on metformin.

@nl

prefLabel

Open-label randomized non-infe ...... is uncontrolled on metformin.

@en

Open-label randomized non-infe ...... is uncontrolled on metformin.

@nl

P1476

Open-label randomized non-infe ...... is uncontrolled on metformin.

@en

P2093

A Stylianou

http://www.w3.org/2001/XMLSchema#string

C Dott

http://www.w3.org/2001/XMLSchema#string

G Atkinson

http://www.w3.org/2001/XMLSchema#string

Glimepiride/Atorvastatin Investigational Team

http://www.w3.org/2001/XMLSchema#string

K LaCroix

http://www.w3.org/2001/XMLSchema#string

K W Min

http://www.w3.org/2001/XMLSchema#string

L Baylor Curtis

http://www.w3.org/2001/XMLSchema#string

N Haque

http://www.w3.org/2001/XMLSchema#string

P Ambery

http://www.w3.org/2001/XMLSchema#string

P2860

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.

Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

Atorvastatin associated liver disease.

P304

1084-1093

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DME.13003

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26484794

http://www.w3.org/2001/XMLSchema#string

P921

metformin